Acadia Pharma press release (NASDAQ:ACAD): Q1 GAAP EPS of $0.10 beats by $0.05. Revenue of
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q1 earnings results on Wednesday, May 8th, after
georgeclerk Taysha Gene Therapies (NASDAQ:TSHA) traded higher on Tuesday after Piper Sandler launched its coverage
Summary: Acadia’s new drug, Daybue, shows promising initial sales, but pimavanserin failed in schizophrenia trials,
Summary: Acadia Pharmaceuticals stock price dropped over 15% after its drug candidate, pimavanserin, failed to
Bet_Noire Mizuho has downgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to neutral, citing the failure of a key
primeimages Stock futures edged higher on Tuesday, following the release of the CPI report. While
wildpixel/iStock via Getty Images Acadia Pharmaceuticals (NASDAQ:ACAD) plunged 15% in after-hours trading on Monday after
Summary: Acadia’s DAYBUE drug to treat Rett Syndrome has disappointed recently. DAYBUE patients suffer from
Summary: Shares of Acadia Pharmaceuticals Inc. are stuck in the 20s despite the company’s progress